Nurse Practitioner, Family · Lexington, KY
NPI
1235514621
Since 2015
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
UK Division of Endocrinology 740 S Limestone
Lexington, KY, 40536
Phone (859) 323-2232
Groups this clinician bills Medicare through
Medicare paid, 2024
$17K
284 services
Medicare patients, 2024
105
Average age 66
Drug cost, 2024
$2.3M
4,083 prescriptions
Company payments, 2025
$49.67
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rachel S McNeil was code 99214 (office e&m - established), 190 times for 90 patients. In total Rachel S McNeil billed 284 services in 6 codes, and Medicare paid $17K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-08-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 190 | 90 | $61.63 | $12K |
| 95251 Test - Miscellaneous | Office | 41 | 33 | $21.99 | $902 |
| 99215 Office E&M - Established | Office | 41 | 32 | $93.40 | $3,829 |
By year: 2022 $16K for 330 services; 2023 $13K for 238 services; 2024 $17K for 284 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rachel S McNeil prescribed most often to Medicare patients was Ozempic (Semaglutide), with 421 prescriptions and refills. In total Rachel S McNeil wrote 4,083 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 421 | 531 | 83 | $467K |
| Trulicity Dulaglutide | 308 | 399 | 70 | $367K |
| Jardiance Empagliflozin | 305 | 650 | 89 | $363K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 280 | 569 | 97 | $48K |
| Metformin Hcl Er Metformin Hcl | 228 | 573 | 66 | $2,666 |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 220 | 426 | 84 | $20K |
| Metformin Hcl Generic | 182 | 438 | 56 | $1,593 |
| Novolog Flexpen Insulin Aspart | 175 | 287 | 52 | $50K |
| Mounjaro Tirzepatide | 164 | 185 | 31 | $185K |
| Novolog Mix 70-30 Flexpen Insulin Aspart Prot/Insuln Asp | 98 | 162 | 23 | $38K |
| Baqsimi Glucagon | 83 | 83 | 63 | $46K |
| Humulin R U-500 Kwikpen Insulin Regular, Human | 80 | 83 | 13 | $133K |
| Humalog Kwikpen U-100 Insulin Lispro | 72 | 156 | 39 | $32K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 67 | 130 | 24 | $37K |
| Levothyroxine Sodium Generic | 60 | 146 | 23 | $685 |
Brand drugs: 2,739 claims; generic drugs: 780 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rachel S McNeil $49.67 ($49.67 in general payments such as food, travel and fees) from 1 company. The largest payer was Averitas Pharma Inc. with $49.67.
| Company | Payments | Amount |
|---|---|---|
| Averitas Pharma Inc. | 1 | $49.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.